Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...

Current health news highlights include UK investor backing in Assura's acquisition by PHP, Novo Nordisk's legal affairs over Wegovy drug sales, and Apollo Hospitals' increased AI investments. The CDC ...

Through a trust, Dudum sold about $33.4 million worth of his company's stock on Thursday, according to a filing with the Securities and Exchange Commission put out after Monday's closing bell. The CEO ...